Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: a European routine-care observational study.
Sara Nysom ChristiansenSimon Horskjær RasmussenMikkel OstergaardMarion PonsBrigitte MichelsenKarel PavelkaCatalin CodreanuAdrian CiureaBente GlintborgMaria Jose SantosIsmail SariŽiga RotarBjorn GudbjornssonGary John MacfarlaneHeikki RelasFlorenzo IannoneKarin LaasJohan K WallmanMarleen van de SandeSella Aarrestad ProvanIsabel CastrejonJakub ZavadaCorina MogosanMichael John NissenAnne Gitte LoftAnabela BarcelosYesim ErezKatja Perdan PirkmajerGerdur GrondalGareth T JonesAnna-Mari HokkanenMaria Sole ChimentiSigrid VorobjovDaniela Di GiuseppeTore K KvienLucia Otero-VarelaIrene E van der Horst-BruinsmaMerete Lund HetlandLykke Midtbøll ØrnbjergPublished in: RMD open (2024)
Crude remission/drug retention rates in European secukinumab-treated patients were higher in r-axSpA compared with nr-axSpA patients. In adjusted analyses, secukinumab effectiveness was similar in both groups, suggesting that observed differences were related to factors other than radiographic status.